首页 > 市场调查报告书 > 医疗设备

医学影像诊断核子医学

市场调查报告书

商品编码

1322232

核医学市场 - 全球行业分析、规模、份额、增长、趋势和预测，2023-2031 年

Nuclear Medicine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

出版日期: 2023年06月29日 | 出版商:

Transparency Market Research | 英文 187 Pages | 商品交期: 2-10个工作天内

价格

简介目录图表

核医学市场 - 报告范围

TMR 关于全球核医学市场的报告研究了过去以及当前的增长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了全球核医学市场的收入2017-2031年期间，考虑2023年为基准年，2031年为预测年。该报告还提供了2023年至2031年全球核医学市场的复合年增长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领袖和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解核医学市场。

该报告深入研究了全球核医学市场的竞争格局。全球核医学市场的主要参与者已经确定，并且每一个参与者都已根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球核医学市场参与者的属性。

市场参与者 - 竞争矩阵（按公司层级和规模）
市场份额分析：按公司划分，2022 年
公司简介
- GE Healthcare
- Siemens Healthineers
- Philips Healthcare
- Cardinal Health
- Bracco Imaging SpA
- Curium Pharma
- Eckert & Ziegler
- Jubilant Radiopharma
- Lantheus Medical Imaging
- Nordion, Inc.
- Advanced Accelerator Applications (AAA)
- IBA Radiopharma Solutions
- NorthStar Medical Radioisotopes
- Polatom
- Isotopia Molecular Imaging

简介目录图表

Product Code: TMRGL4672

Nuclear Medicine Market - Scope of Report

TMR's report on the global Nuclear Medicine Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Nuclear Medicine Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Nuclear Medicine Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Nuclear Medicine Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Nuclear Medicine Market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Nuclear Medicine Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Nuclear Medicine Market.

The report delves into the competitive landscape of the global Nuclear Medicine Market. Key players operating in the global Nuclear Medicine Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Nuclear Medicine Market profiled in this report.

Key Questions Answered in Global Nuclear Medicine Market Report:

What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
What are the opportunities in the global Nuclear Medicine Market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Nuclear Medicine Market - Research Objectives and Research Approach

The comprehensive report on the global Nuclear Medicine Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Nuclear Medicine Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Nuclear Medicine.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Nuclear Medicine Market

4. Market Overview

4.1. Introduction
- 4.1.1. Segment Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Nuclear Medicine Market Analysis and Forecast, 2017-2031

5. Key Insights

5.1. Technological Advancements
5.2. List of FDA Approved Radioisotopes
5.3. No. of Nuclear Medicine Centers in Major Countries
5.4. COVID-19 Pandemic Impact on Industry

6. Global Nuclear Medicine Market Analysis and Forecast, by Type

6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017-2031
- 6.3.1. Diagnostic Nuclear Medicine
  - 6.3.1.1. PECT Radiopharmaceuticals
  - 6.3.1.2. PET Radiopharmaceuticals
- 6.3.2. Therapeutic Nuclear Medicine
  - 6.3.2.1. Alpha Emitters
  - 6.3.2.2. Beta Emitters
  - 6.3.2.3. Brachytherapy Isotopes
6.4. Market Attractiveness Analysis, by Type

7. Global Nuclear Medicine Market Analysis and Forecast, by Application

7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017-2031
- 7.3.1. Cardiology
- 7.3.2. Neurology
- 7.3.3. Oncology
- 7.3.4. Pulmonology
- 7.3.5. Gastroenterology
- 7.3.6. Others
7.4. Market Attractiveness Analysis, by Application

8. Global Nuclear Medicine Market Analysis and Forecast, by End-user

8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017-2031
- 8.3.1. Hospitals
- 8.3.2. Diagnostic Centers
  - 8.3.2.1. Individual Practice
  - 8.3.2.2. Group Practice
- 8.3.3. Research Institutes
8.4. Market Attractiveness Analysis, by End-user

9. Global Nuclear Medicine Market Analysis and Forecast, by Region

9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Nuclear Medicine Market Analysis and Forecast

10.1. Introduction
- 10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017-2031
- 10.2.1. Diagnostic Nuclear Medicine
  - 10.2.1.1. PECT Radiopharmaceuticals
  - 10.2.1.2. PET Radiopharmaceuticals
- 10.2.2. Therapeutic Nuclear Medicine
  - 10.2.2.1. Alpha Emitters
  - 10.2.2.2. Beta Emitters
  - 10.2.2.3. Brachytherapy Isotopes
10.3. Market Value Forecast, by Application, 2017-2031
- 10.3.1. Cardiology
- 10.3.2. Neurology
- 10.3.3. Oncology
- 10.3.4. Pulmonology
- 10.3.5. Gastroenterology
- 10.3.6. Others
10.4. Market Value Forecast, by End-user, 2017-2031
- 10.4.1. Hospitals
- 10.4.2. Diagnostic Centers
  - 10.4.2.1. Individual Practice
  - 10.4.2.2. Group Practice
- 10.4.3. Research Institutes
10.5. Market Value Forecast, by Country, 2017-2031
- 10.5.1. U.S.
- 10.5.2. Canada
10.6. Market Attractiveness Analysis
- 10.6.1. By Type
- 10.6.2. By Application
- 10.6.3. By End-user
- 10.6.4. By Country

11. Europe Nuclear Medicine Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017-2031
- 11.2.1. Diagnostic Nuclear Medicine
  - 11.2.1.1. PECT Radiopharmaceuticals
  - 11.2.1.2. PET Radiopharmaceuticals
- 11.2.2. Therapeutic Nuclear Medicine
  - 11.2.2.1. Alpha Emitters
  - 11.2.2.2. Beta Emitters
  - 11.2.2.3. Brachytherapy Isotopes
11.3. Market Value Forecast, by Application, 2017-2031
- 11.3.1. Cardiology
- 11.3.2. Neurology
- 11.3.3. Oncology
- 11.3.4. Pulmonology
- 11.3.5. Gastroenterology
- 11.3.6. Others
11.4. Market Value Forecast, by End-user, 2017-2031
- 11.4.1. Hospitals
- 11.4.2. Diagnostic Centers
  - 11.4.2.1. Individual Practice
  - 11.4.2.2. Group Practice
- 11.4.3. Research Institutes
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.5.1. Germany
- 11.5.2. U.K.
- 11.5.3. France
- 11.5.4. Italy
- 11.5.5. Spain
- 11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
- 11.6.1. By Type
- 11.6.2. By Application
- 11.6.3. By End-user
- 11.6.4. By Country/Sub-region

12. Asia Pacific Nuclear Medicine Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017-2031
- 12.2.1. Diagnostic Nuclear Medicine
  - 12.2.1.1. PECT Radiopharmaceuticals
  - 12.2.1.2. PET Radiopharmaceuticals
- 12.2.2. Therapeutic Nuclear Medicine
  - 12.2.2.1. Alpha Emitters
  - 12.2.2.2. Beta Emitters
  - 12.2.2.3. Brachytherapy Isotopes
12.3. Market Value Forecast, by Application, 2017-2031
- 12.3.1. Cardiology
- 12.3.2. Neurology
- 12.3.3. Oncology
- 12.3.4. Pulmonology
- 12.3.5. Gastroenterology
- 12.3.6. Others
12.4. Market Value Forecast, by End-user, 2017-2031
- 12.4.1. Hospitals
- 12.4.2. Diagnostic Centers
  - 12.4.2.1. Individual Practice
  - 12.4.2.2. Group Practice
- 12.4.3. Research Institutes
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.5.1. China
- 12.5.2. Japan
- 12.5.3. India
- 12.5.4. Australia & New Zealand
- 12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
- 12.6.1. By Type
- 12.6.2. By Application
- 12.6.3. By End-user
- 12.6.4. By Country/Sub-region

13. Latin America Nuclear Medicine Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017-2031
- 13.2.1. Diagnostic Nuclear Medicine
  - 13.2.1.1. PECT Radiopharmaceuticals
  - 13.2.1.2. PET Radiopharmaceuticals
- 13.2.2. Therapeutic Nuclear Medicine
  - 13.2.2.1. Alpha Emitters
  - 13.2.2.2. Beta Emitters
  - 13.2.2.3. Brachytherapy Isotopes
13.3. Market Value Forecast, by Application, 2017-2031
- 13.3.1. Cardiology
- 13.3.2. Neurology
- 13.3.3. Oncology
- 13.3.4. Pulmonology
- 13.3.5. Gastroenterology
- 13.3.6. Others
13.4. Market Value Forecast, by End-user, 2017-2031
- 13.4.1. Hospitals
- 13.4.2. Diagnostic Centers
- 13.4.3. Research Institutes
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
- 13.6.1. By Type
- 13.6.2. By Application
- 13.6.3. By End-user
- 13.6.4. By Country/Sub-region

14. Middle East & Africa Nuclear Medicine Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017-2031
- 14.2.1. Diagnostic Nuclear Medicine
  - 14.2.1.1. PECT Radiopharmaceuticals
  - 14.2.1.2. PET Radiopharmaceuticals
- 14.2.2. Therapeutic Nuclear Medicine
  - 14.2.2.1. Alpha Emitters
  - 14.2.2.2. Beta Emitters
  - 14.2.2.3. Brachytherapy Isotopes
14.3. Market Value Forecast, by Application, 2017-2031
- 14.3.1. Cardiology
- 14.3.2. Neurology
- 14.3.3. Oncology
- 14.3.4. Pulmonology
- 14.3.5. Gastroenterology
- 14.3.6. Others
14.4. Market Value Forecast, by End-user, 2017-2031
- 14.4.1. Hospitals
- 14.4.2. Diagnostic Centers
  - 14.4.2.1. Individual Practice
  - 14.4.2.2. Group Practice
- 14.4.3. Research Institutes
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.5.1. GCC Countries
- 14.5.2. South Africa
- 14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
- 14.6.1. By Type
- 14.6.2. By Application
- 14.6.3. By End-user
- 14.6.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2022
15.3. Company Profiles
- 15.3.1. GE Healthcare
  - 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.1.2. Type Portfolio
  - 15.3.1.3. Financial Overview
  - 15.3.1.4. SWOT Analysis
  - 15.3.1.5. Strategic Overview
- 15.3.2. Siemens Healthineers
  - 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.2.2. Type Portfolio
  - 15.3.2.3. Financial Overview
  - 15.3.2.4. SWOT Analysis
  - 15.3.2.5. Strategic Overview
- 15.3.3. Philips Healthcare
  - 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.3.2. Type Portfolio
  - 15.3.3.3. Financial Overview
  - 15.3.3.4. SWOT Analysis
  - 15.3.3.5. Strategic Overview
- 15.3.4. Cardinal Health
  - 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.4.2. Type Portfolio
  - 15.3.4.3. Financial Overview
  - 15.3.4.4. SWOT Analysis
  - 15.3.4.5. Strategic Overview
- 15.3.5. Bracco Imaging S.p.A.
  - 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.5.2. Type Portfolio
  - 15.3.5.3. Financial Overview
  - 15.3.5.4. SWOT Analysis
  - 15.3.5.5. Strategic Overview
- 15.3.6. Curium Pharma
  - 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.6.2. Type Portfolio
  - 15.3.6.3. Financial Overview
  - 15.3.6.4. SWOT Analysis
  - 15.3.6.5. Strategic Overview
- 15.3.7. Eckert & Ziegler
  - 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.7.2. Type Portfolio
  - 15.3.7.3. Financial Overview
  - 15.3.7.4. SWOT Analysis
  - 15.3.7.5. Strategic Overview
- 15.3.8. Jubilant Radiopharma
  - 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.8.2. Type Portfolio
  - 15.3.8.3. Financial Overview
  - 15.3.8.4. SWOT Analysis
  - 15.3.8.5. Strategic Overview
- 15.3.9. Lantheus Medical Imaging
  - 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.9.2. Type Portfolio
  - 15.3.9.3. Financial Overview
  - 15.3.9.4. SWOT Analysis
  - 15.3.9.5. Strategic Overview
- 15.3.10. Nordion, Inc.
  - 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.10.2. Type Portfolio
  - 15.3.10.3. Financial Overview
  - 15.3.10.4. SWOT Analysis
  - 15.3.10.5. Strategic Overview
- 15.3.11. Advanced Accelerator Applications (AAA)
  - 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.11.2. Type Portfolio
  - 15.3.11.3. Financial Overview
  - 15.3.11.4. SWOT Analysis
  - 15.3.11.5. Strategic Overview
- 15.3.12. IBA Radiopharma Solutions
  - 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.12.2. Type Portfolio
  - 15.3.12.3. Financial Overview
  - 15.3.12.4. SWOT Analysis
  - 15.3.12.5. Strategic Overview
- 15.3.13. NorthStar Medical Radioisotopes
  - 15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.13.2. Type Portfolio
  - 15.3.13.3. Financial Overview
  - 15.3.13.4. SWOT Analysis
  - 15.3.13.5. Strategic Overview
- 15.3.14. Polatom
  - 15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.14.2. Type Portfolio
  - 15.3.14.3. Financial Overview
  - 15.3.14.4. SWOT Analysis
  - 15.3.14.5. Strategic Overview
- 15.3.15. Isotopia Molecular Imaging
  - 15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.15.2. Type Portfolio
  - 15.3.15.3. Financial Overview
  - 15.3.15.4. SWOT Analysis
  - 15.3.15.5. Strategic Overview

简介目录图表

List of Table

Table 01: Global Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 02: Global Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 03: Global Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 04: Global Nuclear Medicine Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America Nuclear Medicine Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 06: North America Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 07: North America Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 08: North America Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 09: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 10: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 11: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 12: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 13: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 15: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 16: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 17: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 19: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 20: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 23: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 24: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figure

Figure 01: Global Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Nuclear Medicine Market Value Share, by Type, 2022
Figure 03: Global Nuclear Medicine Market Value Share, by Application, 2022
Figure 04: Global Nuclear Medicine Market Value Share, by End-user, 2022
Figure 05: Global Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
Figure 06: Global Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
Figure 07: Global Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
Figure 08: Global Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031
Figure 09: Global Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
Figure 10: Global Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031
Figure 13: Global Nuclear Medicine Market Value Share Analysis, by Region, 2022 and 2031
Figure 14: Global Nuclear Medicine Market Attractiveness Analysis, by Region, 2023-2031
Figure 15: North America Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
Figure 16: North America Nuclear Medicine Market Value Share Analysis, by Country, 2022 and 2031
Figure 17: North America Nuclear Medicine Market Attractiveness Analysis, by Country, 2023-2031
Figure 18: North America Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
Figure 19: North America Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
Figure 20: North America Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
Figure 21: North America Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031
Figure 22: North America Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
Figure 23: North America Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031
Figure 24: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
Figure 25: Europe Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 26: Europe Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 27: Europe Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
Figure 28: Europe Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
Figure 29: Europe Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
Figure 30: Europe Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031
Figure 29: Europe Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
Figure 30: Europe Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031
Figure 31: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
Figure 32: Asia Pacific Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 33: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 34: Asia Pacific Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
Figure 35: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
Figure 36: Asia Pacific Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
Figure 37: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031
Figure 38: Asia Pacific Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
Figure 39: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031
Figure 40: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
Figure 41: Latin America Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 42: Latin America Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 43: Latin America Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
Figure 44: Latin America Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
Figure 45: Latin America Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
Figure 46: Latin America Nuclear Medicine Market Attractiveness Analysis, by Application, 2023-2031
Figure 47: Latin America Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
Figure 48: Latin America Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031
Figure 49: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
Figure 50: Middle East & Africa Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 51: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 52: Middle East & Africa Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
Figure 53: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
Figure 54: Middle East & Africa Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
Figure 55: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031
Figure 56: Middle East & Africa Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
Figure 57: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, by End-user, 2023-2031
Figure 58: Global Nuclear Medicine Market Share Analysis By Company (2022)